000			01819nam a2200361Ia 4500
001			ocm51932126
003			OCoLC
005			20180312141842.0
007			he bmb024bbca
008			030327s2002 dcu bb f000 0 eng d
040			_aFPS _beng _cFPS _dOCLCQ _dOCLCO _dOCLCQ _dOCLCA _dGPO _dMvI
043			_an-us---
074			_a1019-B-01 (MF)
086	0		_aY 4.C 73/8:107-140
099			_aY 4.C 73/8:107-140
110	1		_aUnited States. _bCongress. _bHouse. _bCommittee on Energy and Commerce. _bSubcommittee on Health.
245	1	0	_aExamining issues related to competition in the pharmaceutical marketplace : _ba review of the FTC report, generic drug entry prior to patent expiration : hearing before ... 107th Congress, 2nd session, October 9, 2002.
246	3	0	_aGeneric drug entry prior to patent expiration
260			_aWashington, DC : _bU.S. G.P.O., _c2002.
300			_aiii, 142 pages ; _c24 cm
336			_atext _btxt _2rdacontent
337			_amicroform _bh _2rdamedia
338			_amicrofiche _bhe _2rdacarrier
500			_a"Serial no. 107-140."
504			_aIncludes bibliographical references.
533			_aMicrofiche. _bWashington : _cSupt. of Docs., U.S. G.P.O., _d2003. _e2 microfiches : negative.
500			_aShipping list no.:2003-0144-M.
500			_aCRDP Program record.
650		0	_aGeneric drugs.
650		0	_aCompetition.
650		0	_aPharmaceutical industry.
776	0	8	_iOnline version: _aUnited States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health. _tExamining issues related to competition in the pharmaceutical marketplace _w(OCoLC)852784168
776	0	8	_iPrint version: _aUnited States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health. _tExamining issues related to competition in the pharmaceutical marketplace _w(DLC) 2003387711 _w(OCoLC)51543393
999			_c269569 _d269569